ALZN
Alzamend Neuro, Inc.
Key Financials
Net Income
$-4514853
↑ 54.6%
Operating Income
$-4496824
↑ 54.7%
EPS (Diluted)
$-11.32
↑ 23.0%
Total Assets
$4.6M
↑ 628.8%
Cash & Equivalents
$3.9M
↑ 950.0%
Total Liabilities
$634761.00
↓ 80.3%
Shareholders' Equity
$4.0M
↑ 253.0%
Operating Cash Flow
$-6568186.00
↑ 20.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ALZN |
| Company Name | Alzamend Neuro, Inc. |
| CIK | 1677077 |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0430 |
| State of Incorporation | DE |
| Phone | 844-722-6333 |